Mastitis is a breast infection, which results in breast pain, swelling, warmth, and redness. In
most cases, lactation mastitis occurs within the first six to 12 weeks after giving birth
(postpartum), but it can happen later during the breastfeeding. The major symptoms of
mastitis include breast tenderness or warmth to the touch, malaise, breast swelling, pain or
a burning sensation continuously or while breastfeeding, skin redness, often in a wedge-
shaped pattern, high fever and others.
The Global Mastitis Market is expected to grow at a CAGR of ~7.6 % during the forecast
period 2017-2023.
According to the WHO, breast cancer is the second most common type of cancer in women.
Every year 200,000 new cases are diagnosed worldwide and the number is continuously
increasing. Prevalence of breast cancer is more common in developed countries as
compared to developing countries. The global breast cancer market is driven by increasing
number of females having breast cancer. Adoption of an unhealthy lifestyle, exposure to
harmful radiation, increasing female geriatric population, and increasing government
initiatives also contributed to the growth of the market. Since no absolute treatment is
available to completely cure the disease, there is a scope for developing effective
treatments. On another hand, the high cost of the treatment, adverse effects associated
with the therapy, and long approval time for the drugs may restrain the growth of the
market. However, the high cost of the treatment is likely to affect the growth of the market,
negatively.
Segmentations
The Global Mastitis Market is segmented on the basis of types, diagnosis, treatment, and
end users.
Based on the types, the market is segmented into contagious mastitis and environmental
mastitis.
On the basis of the diagnosis, the market is segmented into the physical examination and
others.
On the basis of the treatment, the market is segmented into antibiotics, pain relievers,
surgery, and others. The pain relievers are further segmented into acetaminophen,
ibuprofen, and others. Moreover, acetaminophen is segmented into Tylenol and others.
Ibuprofen is further segmented into Advil, Motrin IB, and others.
On the basis of the end users, the market is segmented into hospital & clinics, research
centers, and others.
Top Key Players
Pfizer (U.S.), Novartis AG (Switzerland), Oncogenex (U.S.), Apthera Inc (U.K), BioNumerik
Pharmaceuticals (U.S.), Oncothyreon Inc (U.S.), Astellas (Japan), Bipar Sciences (U.S.),
Puma Biotechnology (U.S.), Sanofi S.A. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca
(U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (U.K.), Genentech (U.S.),
Teva Pharmaceutical Industries (Israel), Sun Pharmaceutical Industries Ltd (India), Accord
Healthcare, Inc. (India), Gilead Sciences, Inc. (U.S.), and others.
Get Sample Copy at https://www.marketresearchfuture.com/sample_request/5379 .
Regional Analysis
The Americas dominate the global mastitis market owing to the increasing number of
patients with various cancer such as mastitis, and rare diseases. Due to rapidly increasing
patient population, governments have started supporting the manufacturers for the
development of new and better drugs. Additionally, well-developed technology, high
healthcare expenditure, and strong government support for research & development have
fueled the growth of the market in this region.
Europe commands the second largest market for mastitis, which is followed by the Asia
Pacific. Availability of funds, increasing need for better treatment options, and strong
government support drive the growth of the market in Europe. Germany, France & the U.K
are the major contributors to the European market growth.